Wednesday, July 8, 2026

Vertex to buy Crinetics for about $10 billion

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals in a cash transaction that expands its position in rare endocrine diseases. Under the definitive agreement, Vertex will pay 85.00 US dollars per Crinetics share, valuing the company at about 10.0 billion US dollars in equity value, or approximately 8.8 billion US dollars net of estimated cash acquired.

The boards of both companies have unanimously approved the deal. Closing is expected in the third quarter of 2026, subject to customary conditions, including regulatory clearances and approval by Crinetics shareholders.

Commercial acromegaly medicine at the center

The acquisition gives Vertex a marketed product and late-stage endocrine pipeline assets. Crinetics’ lead commercial medicine is PALSONIFY (paltusotine), a once-daily oral therapy for adults with acromegaly. The medicine was approved by the US Food and Drug Administration in September 2025 and, according to the companies, has also recently received approval from the European Medicines Agency. It remains under review by other regulators.

Acromegaly is a rare chronic hormonal disorder most often caused by a benign pituitary tumor that leads to excess growth hormone. The companies estimate that about 20,000 diagnosed people live with the condition in the United States. Before PALSONIFY, treatment relied largely on injectable somatostatin analogues, which may require administration by healthcare professionals and are not suitable or effective for all patients.

Vertex said PALSONIFY has shown early commercial momentum after launch. The company sees blockbuster potential in acromegaly and plans to apply its rare disease commercialization capabilities to the product.

Atumelnant adds Phase 3 endocrine asset

Crinetics’ most advanced pipeline candidate is atumelnant, a once-daily oral ACTH receptor antagonist in Phase 3 development for classic congenital adrenal hyperplasia, or CAH. The disease is a rare inherited adrenal disorder associated with impaired cortisol synthesis and, in most cases, excess androgen production.

The companies cite 17,000 addressable patients with classic CAH in the United States. In Phase 2 studies, patients treated with atumelnant achieved near normalization of elevated androgen levels while receiving physiologic replacement doses of glucocorticoids, according to the announcement. To date, no treatment-related severe or serious adverse events have been reported.

Atumelnant is also being studied in ACTH-dependent Cushing’s syndrome. The Phase 3 CALM-CAH trial and a Phase 1/2b trial in that indication are currently enrolling patients.

Financial expectations and financing

Vertex estimates that the acquired assets could generate more than 5 billion US dollars in combined annual peak revenue. The company expects the transaction to contribute to revenue growth immediately through the PALSONIFY launch and to become accretive to non-GAAP operating income in 2029.

The acquisition is expected to be financed with cash on hand and debt. Vertex has also secured 4.5 billion US dollars in fully committed bridge financing from Bank of America and Morgan Stanley Senior Funding.

For Vertex, the transaction broadens a portfolio that already includes approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain. Crinetics brings additional disclosed programs, including work in neuroendocrine tumors and other endocrine targets.